WASHINGTON,
A vaccine that
protects against four strains of the human papillomavirus, which can
lead to cervical cancer, does not increase the risk of blood clots in
women, researchers said Tuesday.
The findings in the
Journal of the American Medical Association (JAMA) are based on 500,000
girls and women aged 10 to 44 who received the HPV vaccine between 2006
and 2013.
Using data from national registries,
researchers in Denmark found no evidence of an increased risk of venous
thromboembolism (VTE) in the 42 days after the shot, which they defined
as the main risk period.
Of the 500,000, there were 4,375 cases of blood clots, and of those, 889 had been vaccinated during the study period.
RISK FACTORS
When
researchers adjusted for use of oral contraceptives, which can increase
the risk of blood clots, they found no association between VTE and the
vaccine.
"Our results, which were consistent after
adjustment for oral contraceptive use and in girls and young women as
well as mid-adult women, do not provide support for an increased risk of
VTE following quadrivalent HPV vaccination," the study said.
"Safety
concerns can compromise immunization programs to the detriment of
public health, and timely evaluations of such concerns are essential."
The
JAMA report said a pair of earlier studies had suggested a link between
the Gardasil vaccine, made by Merck, and a higher risk of blood clots.
The
Centres for Disease Control and Prevention said in 2009 that there was
an increase in patient reports of blood clots after the vaccination.
However,
on further review, the CDC said 90 percent of those "had a known risk
factor for blood clots, such as taking oral contraceptives (birth
control pills)."
US health authorities recommend the HPV vaccine for boys and girls before they become sexually active.
The
vaccine aims to prevent the spread of HPV, which is the most common
sexually transmitted infection. Certain HPV strains can cause cancers of
the cervix, head, neck and anus.
Comments
Post a Comment